Tour de Gymnáziá 2025 – Final Report
On May 23, 2025, CEO of MultiplexDX successfully concluded this year’s Tour de Gymnáziá. Over the course of the program, five Slovak high schools were visited: Gymnázium Poštová 9 in Košice, Gymnázium Ľ. Štúra 26 in Michalovce, Gymnázium Lipany, Gymnázium Jána Adama Raymana in Prešov, and Gymnázium Konštantínova 2 in Prešov.
The tour reached more than 500 students with an interest in chemistry, biology, and medicine. Many were accomplished competitors in national science Olympiads and seminars, representing the next generation of Slovak scientific talent.
Through sharing the story of our founder’s career in science and biotechnology, the sessions highlighted both the challenges and opportunities of pursuing research. From setbacks and failed experiments to internationally recognized publications, patents, and innovations, students gained insights into how perseverance and critical thinking can lead to success in science and entrepreneurship.
However, the tour also revealed a concerning trend: over 75% of the students expressed plans to study abroad, a significant increase compared to previous years. This reflects a growing challenge for Slovak universities and society at large, as many talented young people may not return to their country. MultiplexDX strongly believes that creating a supportive environment for science and innovation in Slovakia is essential to reverse this trend.
We extend our sincere gratitude to SOVVA for organizing this year’s tour and for their continued efforts in promoting science through initiatives such as European Researchers’ Night (Noc vedy). We encourage everyone to participate in this inspiring event later this year.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
